Fertility clinics push back
By Alison Motluk,
HeyReprotech Newsletter
| 04. 21. 2020
Advisory bodies generally agree that now is not the time for full-on fertility treatment. Some prominent clinics beg to differ.
Several of the fertility world's top advisory bodies have strongly urged fertility clinics to stop or severely scale back services during the COVID-19 pandemic.
The European Society of Human Reproduction and Embryology (ESHRE) last week reaffirmed that fertility doctors, like other medical professionals, have a "duty" to not make this crisis worse and so should not be providing non-urgent services. Only people facing cancer treatment should be exceptions, they advised.
They underscored the reasons for their decision: to avoid any coronavirus-related pregnancy complications, to mitigate the unknown risks of parent-to-child transmission, to keep medical resources on the front lines and to follow the rules on physical distancing.
The American Society for Reproductive Medicine (ASRM) first issued guidelines about COVID-19 on March 17 and have since provided two updates. In the most recent, on April 14, they advised that "it is not yet prudent to resume non-emergency infertility procedures." They said that clinics should avoid starting new treatment cycles, cancel all transfers, suspend non-urgent procedures and minimize in-person interactions. The Canadian Fertility and Andrology Society (CFAS) has been advocating...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...